Abstract
Phosphoinositide 3-kinase (PI3K) is an enzyme involved in the signaling and control of essential cell functions with respect to receptor tyrosine kinase (RTK), for which they are activated. PI3K is involved in some types of cancers in humans, as has been observed in breast, hepatocellular, and colorectal, where, in this latter one, it was only the gene whose mutation was showed. When this gene mutation occurs, overstimulation of this pathway may occur, resulting in an overexpression of tyrosine kinase pathway and inactivation of the Phosphatase and tensin homolog (PTEN), which is a tumor suppressor most frequently deregulated in cancer. The present study aimed to investigate the known inhibitors of PI3K-alpha, deposited in databases such as Binding DB and PDB, in order to draw a profile of physicochemical and pharmacokinetic properties of the most active inhibitors for this enzyme. From this, nine proposals of potential new PI3K inhibitors were developed, which were evaluated with respect to pharmacokinetic and physicochemical properties, activity and toxicity predictions, as well as synthetic accessibility. The results suggest that some of the proposals may be promising new PIK3 inhibitors, containing drug properties.
Keywords: Cancer therapy, medicinal chemistry, phosphoinositide 3-kinase (PI3K) inhibitors.
Graphical Abstract
Current Bioactive Compounds
Title:Computational Medicinal Chemistry to Design Novel Phosphoinositide 3- Kinase (PI3K) Alpha Inhibitors in View of Cancer
Volume: 10 Issue: 3
Author(s): Lorane I. Hage-Melim, Cleydson B.R. Santos, Joao G. Poiani, Miguel de Menezes Vaidergom, Eduardo S. Manzolli and Carlos H.T. de Paula da Silva
Affiliation:
Keywords: Cancer therapy, medicinal chemistry, phosphoinositide 3-kinase (PI3K) inhibitors.
Abstract: Phosphoinositide 3-kinase (PI3K) is an enzyme involved in the signaling and control of essential cell functions with respect to receptor tyrosine kinase (RTK), for which they are activated. PI3K is involved in some types of cancers in humans, as has been observed in breast, hepatocellular, and colorectal, where, in this latter one, it was only the gene whose mutation was showed. When this gene mutation occurs, overstimulation of this pathway may occur, resulting in an overexpression of tyrosine kinase pathway and inactivation of the Phosphatase and tensin homolog (PTEN), which is a tumor suppressor most frequently deregulated in cancer. The present study aimed to investigate the known inhibitors of PI3K-alpha, deposited in databases such as Binding DB and PDB, in order to draw a profile of physicochemical and pharmacokinetic properties of the most active inhibitors for this enzyme. From this, nine proposals of potential new PI3K inhibitors were developed, which were evaluated with respect to pharmacokinetic and physicochemical properties, activity and toxicity predictions, as well as synthetic accessibility. The results suggest that some of the proposals may be promising new PIK3 inhibitors, containing drug properties.
Export Options
About this article
Cite this article as:
Hage-Melim I. Lorane, Santos B.R. Cleydson, Poiani G. Joao, Vaidergom de Menezes Miguel, Manzolli S. Eduardo and Silva H.T. de Paula da Carlos, Computational Medicinal Chemistry to Design Novel Phosphoinositide 3- Kinase (PI3K) Alpha Inhibitors in View of Cancer, Current Bioactive Compounds 2014; 10 (3) . https://dx.doi.org/10.2174/157340721003141013142410
DOI https://dx.doi.org/10.2174/157340721003141013142410 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Implications of Nanoscale Based Drug Delivery Systems in Delivery and Targeting Tubulin Binding Agent, Noscapine in Cancer Cells
Current Drug Metabolism Strategies for Target-Specific Contrast Agents for Magnetic Resonance Imaging
Current Molecular Imaging (Discontinued) Genetic and Epigenetic Studies for Determining Molecular Targets of Natural Product Anticancer Agents
Current Cancer Drug Targets Mesenchymal Stem Cells: An Emerging Tool for Cancer Targeting and Therapy
Current Stem Cell Research & Therapy Changes in the Expression of the Alzheimers Disease-Associated Presenilin Gene in Drosophila Heart Leads to Cardiac Dysfunction
Current Alzheimer Research Recombinant Interleukin-12 for Immunotherapy: A Double-Sided Sword
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents miRNAs in Melanoma: Tumor Suppressors and Oncogenes with Prognostic Potential
Current Medicinal Chemistry The Vitamin D Saga: Breaking Dawn
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Mechanism of Cancer Drug Resistance and the Involvement of Noncoding RNAs
Current Medicinal Chemistry Development of a PBPK Model for Monoclonal Antibodies and Simulation of Human and Mice PBPK of a Radiolabelled Monoclonal Antibody
Current Pharmaceutical Design The Dendritic Cell-T Cell Synapse as a Determinant of Autoimmune Pathogenesis
Current Pharmaceutical Design Long-Term Safety from the Raltegravir Clinical Development Program
Current HIV Research Recent Progress in FKBP Ligand Development
Current Molecular Pharmacology Dehydroepiandrosterone and Its Derivatives: Potentially Novel Anti-Proliferative and Chemopreventive Agents
Current Pharmaceutical Design Protein Arginine Methyltransferase 1 and its Dynamic Regulation Associated with Cellular Processes and Diseases
Protein & Peptide Letters NHE-1: A Promising Target for Novel Anti-cancer Therapeutics
Current Pharmaceutical Design Synthesis and Pharmacological Effects of the Anti-Cancer Agent 2-Methoxyestradiol
Current Pharmaceutical Design Selenium Role in Reproduction, Pregnant/Postpartum Women and Neonates: A Current Study
Current Nutrition & Food Science Synthesis of a Tyr-Tyr Dipeptide Library and Evaluation Against Tumor Cells
Medicinal Chemistry Recent Advances in Nanoparticle Carriers for Coordination Complexes
Current Topics in Medicinal Chemistry